ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...

Proteomics International has secured a US patent for its PromarkerEso, a breakthrough blood test enabling early detection of ...

Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...

Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

In patients with renal cell carcinoma, a phase 2 trial tested neoadjuvant stereotactic ablative radiation therapy to the inferior vena cava tumor thrombus before radical nephrectomy with thrombectomy.

Terrence Wise, 56, tried in vain for months at the MDC Brooklyn jail to get proper treatment as he complained of chest pain ...

Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools.

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...

Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative month for cancer treatment with ...